Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs

Milo Gatti, Massimo Andreoni, Federico Pea, Pierluigi Viale

1Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 2SSD Clinical Pharmacology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 3Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy; 4Infectious Diseases Clinic, University Hospital “Tor Vergata”, Rome, Italy; 5Infectious Disease Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

Abstract: Dalbavancin is a novel, long-acting lipoglycopeptide characterized by a long elimination half-life coupled with excellent in vitro activity against multidrug-resistant Gram-positives. Although it is currently approved only for the treatment of acute bacterial skin and skin structure infections, an ever-growing amount of evidence supports the efficacy of dalbavancin as a long-term therapy in osteomyelitis, prosthetic joint infections, endocarditis, and bloodstream infections. This article provides a critical reappraisal of real-world use of dalbavancin for off-label indications. A search strategy using specific keywords (dalbavancin, osteomyelitis, endocarditis, long-term suppressive therapy, bloodstream infection, pharmacokinetic/pharmacodynamic profile) until April 2021 was performed on the PubMed-MEDLINE database. As for other novel antibiotics, a conundrum between approved indications and potential innovative therapeutic uses has emerged for dalbavancin as well. The promising efficacy in challenging scenarios (i.e., osteomyelitis, endocarditis, prosthetic joint infections), coupled with the unique pharmacokinetic/pharmacodynamic properties, makes dalbavancin a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections. This makes dalbavancin valuable in the current COVID-19 scenario, in which hospitalization and territorial medicine empowerment are unavoidable.

Keywords: dalbavancin, osteomyelitis, endocarditis, long-term suppressive therapy, PK/PD properties, COVID-19

Introduction

Dalbavancin is a novel, long-acting lipoglycopeptide active against Gram-positive pathogens, including multi-drug resistant isolates.1 Long elimination half-life and good tissue penetration represent the main pharmacokinetic features of dalbavancin,2 allowing for long-term efficacy despite the simplified weekly administration regimen. It was approved by the US Food and Drug Administration and the European Medicines Agency in 2014 and 2015 for the management of acute bacterial skin and skin structure infections (ABSSSIs) on an intravenous dosing regimen of 1500 mg as a single infusion or 1000 mg followed by 500 mg one week apart.3,4 Currently, ABSSSIs remain the only approved indication for dalbavancin, although this could represent a non-innovative and inefficient exploitation of its pharmacokinetic/pharmacodynamic (PK/PD) properties. Indeed, as reported for
other novel antibiotics (e.g., ceftazidime-avibactam), a conundrum between approved indications and potential innovative therapeutic uses has emerged for dalbavancin. An ever-growing amount of evidence supports the efficacy of dalbavancin as a long-term therapy for off-label indications, namely osteomyelitis, prosthetic joint infections, endocarditis, and bloodstream infections, in which a treatment for at least 6 weeks is usually required. In the current COVID-19 era, patients requiring prolonged antibiotic therapy after hospital discharge due to severe bacterial infections (e.g., endocarditis or osteomyelitis) are at increased risk for contracting and/or transmitting COVID-19 due to extensive contact with the healthcare system. By virtue of its PK/PD properties, dalbavancin could be a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections, providing an added value in the current COVID-19 scenario, in which ineluctable hospitalization and empowerment of territorial medicine are strongly required. We performed a critical reappraisal of real-world use of dalbavancin for off-label indications, suggesting therapeutic algorithms according to different clinical scenarios.

**Materials and Methods**

A literature search was conducted on PubMed-MEDLINE (from inception until April 2021) in order to retrieve randomized controlled trials (RCTs), prospective or retrospective observational studies, case series, and case reports investigating the use of dalbavancin for off-label indications. Six different main topics focusing on innovative use of dalbavancin were identified by three experts in the field (PV, MA, and FP), namely PK/PD properties, osteomyelitis, endocarditis and bloodstream infections, long-term suppressive therapy, safety, and quality of life. The following terms were searched on PubMed in combination:

dalbavancin, endocarditis, bloodstream infection, osteomyelitis, bone, prosthetic joint, long-term, off-label indication, pharmacokinetic, PK/PD, safety, quality of life.

Only studies in which clinical outcome associated with dalbavancin use was reported for each off-label indication were included. Articles were excluded if: only cumulative efficacy of dalbavancin for different off-label indications was provided; different long-acting lipoglycopeptides were investigated and clinical outcome for each single agent was not provided. There were no language restrictions. For each included study, the following information was extracted: (a) study author and year of publication; (b) study characteristics including study design and sample size; (c) features of the patients including site of infection, proportion of prior antibiotic therapy and duration, dalbavancin dosing schedule, isolated pathogens, and duration of follow-up; (d) types of outcome measurements, including rate of clinical success or improvement, clinical and/or microbiological failure rate, mortality rate, relapse rate, resistance development, and overall proportion of adverse events. Cumulative incidence of the different outcomes was calculated according to each specific dalbavancin off-label indication.

**PK/PD Properties**

Dalbavancin exhibits peculiar PK/PD properties, consisting in a long terminal half-life (approximately 14.4 days), high binding protein (93%), a predominant non-renal clearance, good tissue penetration, and high susceptibility rate (respectively 99.6% and 100.0%) against methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-susceptible *Staphylococcus aureus* (MSSA) isolates according to EUCAST clinical breakpoint (namely 0.125 mg/l). The clearance of dalbavancin was not affected by the presence of cytochrome P450 substrates, cytochrome P450 inhibitors, cytochrome P450 inducers, or selected concomitant medications. Furthermore, age, gender and race had no impact on the pharmacokinetic profile of dalbavancin. The ratio between the mean free-area under the curve and minimum inhibitory concentration (fAUC/MIC) represents the PK/PD parameter best correlating with *in vivo* efficacy of dalbavancin. The fAUC/MIC values for net stasis, 1-log kill, and 2-log kill against *Staphylococcus aureus* were respectively 27.1, 53.3, and 111.1. No dalbavancin dose adjustment is required in mild-moderate renal impairment, any degree of hepatic impairment, and different modalities of renal replacement therapy (i.e., intermittent haemodialysis, peritoneal dialysis, or continuous renal replacement therapy). Dose reduction should be implemented only in patients affected by severe renal impairment. Dalbavancin exhibits *in vitro* a potent activity against established biofilms due to *Staphylococcus aureus*, *Staphylococcus epidermidis*, and vancomycin-susceptible *Enterococci*, thus possibly playing a crucial role in the management of relevant infections characterized by bacterial biofilm production (e.g., endocarditis, osteomyelitis, device-related infections). Notably, dalbavancin is characterized by good tissue penetration in different sites of infection.
Real-World Use of Dalbavancin for off-Label Indications

Comparative Studies

Three studies (two RCTs and one retrospective case-control study) reported a mean dalbavancin penetration into skin blister fluid of 59.6% after a single 1000 mg infusion, resulting in tissue concentrations well above the MIC₉₀ of common gram-positive pathogens implicated in ABSSSIs (including MRSA) for up to 7 days. In a phase I study including 35 healthy subjects receiving a single infusion of 1500 mg dalbavancin, Rappo et al. found a penetration into the epithelial lining fluid of 36%, resulting in dalbavancin lung concentrations exceeding the MIC₉₀ of *Streptococcus pneumoniae* and *Staphylococcus aureus* for at least 7 days. Notably, Dunne et al.² found a mean bone/plasma AUC of 13.1%, suggesting that two-doses dalbavancin 1500 mg infusion administered one week apart may provide tissue exposure over the MIC for *Staphylococcus aureus* for 8 weeks. These findings were recently confirmed in a population PK study including 15 patients affected by osteoarticular infections, in which a two 1500 mg dosing regimen of dalbavancin one week apart may ensure efficacy against both MSSA and MRSA for up to 5 weeks. Consequently, these unique PK/PD properties make dalbavancin a valuable alternative to daily in-hospital intravenous or outpatient antimicrobial regimens in the treatment of long-term Gram-positive infections, posing the basis for its use beyond approved indications.

Table 1

| Case Reports | Real-World Use of Dalbavancin for off-Label Indications |
|--------------|--------------------------------------------------------|
| CR-BSIs      | Overall, 148 patients affected by dalbavancin, resulting in a clinical success rate of 81.1%. Different dalbavancin regimens in terms of dose and duration were administered. Relapse was reported in up to 14.3% of cases. Only three cases of dalbavancin resistance have been reported. In the DALBACEN cohort study, 34 patients affected by IE (15 prosthetic valve IE, 11 native valve IE, and eight cardiac device-related endocarditis) receiving at least one dose of dalbavancin were assessed. Prior antibiotic therapy implementation was reported in 100.0% of cases, with daptomycin (68.6%) being the most frequent agent used. Dalbavancin was administered as a single-dose or loading dose (LD) of 1000–1500 mg followed by 500–1000 mg weekly for up to 10 weeks. Coagulase-negative *Staphylococci* (CoNS) were the most frequent isolated pathogens. At 1-year, clinical success was documented in 85.3%. No relapse was reported. AEs occurred in 4.8% of patients, although none of these were serious. Interestingly, in all the three cases of IE caused by *Enterococcus faecalis* a positive clinical outcome was reported. Tobudic et al.³² assessed the efficacy and safety of dalbavancin for the treatment of infective endocarditis (IE; Table 2). Overall, 148 patients affected by infective endocarditis were treated with dalbavancin, resulting in a clinical success rate of 81.1%. Different dalbavancin regimens in terms of dose and duration were administered. Relapse was reported in up to 14.3% of cases. Only three cases of dalbavancin resistance have been reported. In the DALBACEN cohort study, 34 patients affected by IE (15 prosthetic valve IE, 11 native valve IE, and eight cardiac device-related endocarditis) receiving at least one dose of dalbavancin were assessed. Prior antibiotic therapy implementation was reported in 100.0% of cases, with daptomycin (68.6%) being the most frequent agent used. Dalbavancin was administered as a single-dose or loading dose (LD) of 1000–1500 mg followed by 500–1000 mg weekly for up to 10 weeks. Coagulase-negative *Staphylococci* (CoNS) were the most frequent isolated pathogens. At 1-year, clinical success was documented in 85.3%. No relapse was reported. AEs occurred in 4.8% of patients, although none of these were serious. Interestingly, in all the three cases of IE caused by *Enterococcus faecalis* a positive clinical outcome was reported. Tobudic et al.³²

Table 2

| Case Reports | Real-World Use of Dalbavancin for off-Label Indications |
|--------------|--------------------------------------------------------|
| CR-BSIs      | Overall, 148 patients affected by dalbavancin, resulting in a clinical success rate of 81.1%. Different dalbavancin regimens in terms of dose and duration were administered. Relapse was reported in up to 14.3% of cases. Only three cases of dalbavancin resistance have been reported. In the DALBACEN cohort study, 34 patients affected by IE (15 prosthetic valve IE, 11 native valve IE, and eight cardiac device-related endocarditis) receiving at least one dose of dalbavancin were assessed. Prior antibiotic therapy implementation was reported in 100.0% of cases, with daptomycin (68.6%) being the most frequent agent used. Dalbavancin was administered as a single-dose or loading dose (LD) of 1000–1500 mg followed by 500–1000 mg weekly for up to 10 weeks. Coagulase-negative *Staphylococci* (CoNS) were the most frequent isolated pathogens. At 1-year, clinical success was documented in 85.3%. No relapse was reported. AEs occurred in 4.8% of patients, although none of these were serious. Interestingly, in all the three cases of IE caused by *Enterococcus faecalis* a positive clinical outcome was reported. Tobudic et al.³²

Infective Endocarditis

Eleven observational studies and five case reports assessed the efficacy and safety of dalbavancin for the treatment of infective endocarditis (IE; Table 2). Overall, 148 patients affected by infective endocarditis were treated with dalbavancin, resulting in a clinical success rate of 81.1%. Different dalbavancin regimens in terms of dose and duration were administered. Relapse was reported in up to 14.3% of cases. Only three cases of dalbavancin resistance have been reported.

In the DALBACEN cohort study, 34 patients affected by IE (15 prosthetic valve IE, 11 native valve IE, and eight cardiac device-related endocarditis) receiving at least one dose of dalbavancin were assessed. Prior antibiotic therapy implementation was reported in 100.0% of cases, with daptomycin (68.6%) being the most frequent agent used. Dalbavancin was administered as a single-dose or loading dose (LD) of 1000–1500 mg followed by 500–1000 mg weekly for up to 10 weeks. Coagulase-negative *Staphylococci* (CoNS) were the most frequent isolated pathogens. At 1-year, clinical success was documented in 85.3%. No relapse was reported. AEs occurred in 4.8% of patients, although none of these were serious. Interestingly, in all the three cases of IE caused by *Enterococcus faecalis* a positive clinical outcome was reported. Tobudic et al.³²
| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Dalbavancin | Comparator | Isolates | Duration of Follow-Up | Outcome | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) |
|----------------------------|--------------|----------------|-------------------|-------------|------------|---------|---------------------|---------|--------------------------------------|-------------------------------|
| Rappo et al., 2019<sup>28</sup> | Randomized controlled trial, open-label | 80 | Concomitant bacteremia: 5.7% vs 10.0% | 70 | Standard of care Vancomycin followed by Linezolid or Levofloxacin or Cefotaxime/ Ceftriaxone | 38 MSSA 14 CoNS 9 Anaerobes 7 E. faecalis 4 MRSA 3 Streptococcus spp. 1 E. faecium 5 Others | 42 days 6 months 1 years | Clinical cure at 42-day: 97% vs 88% Clinical cure at 6-months: 95% vs 88% Clinical cure at 1-year: 94% vs 88% | Requirement for additional ABT in dalbavancin group in 1.5% of patients | 1.4% vs 0.0% |
| Raad et al., 2005<sup>29</sup> | Randomized controlled trial, multicentric, Phase 2 | 67 | ICU admission: 24.0% | 33 | CR-BSI 1000 mg day 1 + 500 mg day 8 | 34 Vancomycin 1 g q12h for 14 days | 14 days | Overall success rate: 87.0% (95% CI 73.2–100%) vs 50.0% (95% CI 31.5–68.5%) | None | No difference between arms No serious AE in dalbavancin group |
| Veve et al., 2020<sup>30</sup> | Retrospective case-control study | 215 | ICU admission: 21.9% Vasopressor use: 8.4% | 70 | 49 osteoarticular infections 12 IE 9 other BSI 46% overall BSI 100% prior ABT | 145 (78 vancomycin 67 daptomycin) 53 osteoarticular infections 47 other BSI 45 IE 86% overall BSI | 90 days | 90-day IRR: 17% vs 28% (p = 0.12) 90-day mortality rate: 3% vs 3% (p = 1.00) Dalbavancin use was independently associated with lower IRR (OR: 0.10; 95% CI: 0.04–0.31) | Relapse with dalbavancin: 6% | 3% vs 14% (p=0.013) |

Abbreviations: ABT, antibiotic therapy; AEs, adverse events; CI, confidence interval; CoNS, coagulase-negative Staphylococcus; CR-BSI, catheter-related bloodstream infections; ICU, intensive care unit; IE, infective endocarditis; IRR, infection-related readmission; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; OR, odds ratio.
| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Dalbavancin Regimen | Isolates | Duration of Follow-Up | Outcome | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) |
|----------------------------|--------------|----------------|-------------------|-----------------------------|---------------------|----------|----------------------|---------|-------------------------------|-----------------------------|
| Hidalgo-Tenorio et al., 2019 | Retrospective cohort study, multicentric | 34 | 15 prosthetic valve IE 11 native IE 8 CDE 31 definite – 3 probable Surgical treatment 91.6% OPAT 88.6% | 100.0% (median 28 days) 68.6% daptomycin 28.6% ceftriaxone 22.9% vancomycin 8.6% linezolid | Dalbavancin 1000–1500 mg (LD or single-dose) + 500–1000 mg (from 1 to 10 weeks) | 15 CoNS 7 MSSA 7 Streptococcus spp. 3 MRSA 3 E. faecalis | 12 months | Clinical success: 85.3% Microbiological eradication: 97.1% Mortality rate: 0.0% | Relapse 0.0% 4.8% (not serious) |
| Tobudic et al., 2018 | Retrospective cohort study | 27 | 16 native valve IE 6 prosthetic valve IE 5 CDE Surgical treatment 59.3% OPAT 85.2% | 88.9% (range 1–5 weeks) | Dalbavancin 1000 mg (LD) + 500 mg once-weekly or 1500 mg (LD) + 1000 mg twice-weekly Median duration: 6 weeks (33.3% once-weekly regimen; 66.7% twice-weekly regimen) | 9 S. aureus 4 S. epidermidis 4 S. sanguinis 4 E. faecalis 2 S. hominis 2 S. equi 1 S. mitis 1 S. caprae 1 Aerococcus urinae | 6 months | Clinical success: 92.6% Microbiological eradication: 92.6% Mortality rate: 3.7% | Resistance development: 3.7% 7.4% (not serious) |
| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Dalbavancin Regimen | Isolates | Duration of Follow-Up | Outcome | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) |
|---------------------------|--------------|----------------|------------------|-------------------------------|---------------------|---------|----------------------|---------|-------------------------------------|---------------------------------|
| Wunsch et al., 2019 | Retrospective cohort study, multicentric | 25 (101 overall patients included in the study) | 15 native IE, 6 prosthetic IE, 4 CDE | 49% OPAT | 100.0% | Dalbavancin 1500 mg single dose or 1500 mg + 1500 mg or 1000 mg + 500 mg | 28 CoNS, 14 MSSA, 8 MRSA, 7 Enterococcus spp, 5 Streptococcus spp, 4 P. acnes, 21 Others | 90 days after the last dose of dalbavancin | Overall clinical success: 89% (92% endocarditis), 90-day mortality rate: 5% (4% endocarditis), Overall clinical failure: 5% (4% endocarditis) | NA |
| Dinh et al., 2019 | Retrospective cohort study, multicentric | 19 (75 overall patients included in the study) | 10 prosthetic valve IE, 9 native IE | OPAT 49.3% | 98.7% | Dalbavancin 1000–1500 mg single-dose or 1000 mg + 500 mg or 1000 mg + 1000 mg or 1500 mg/weekly up to >4 doses | 32 CoNS, 23 MSSA, 14 MRSA, 5 E. faecalis, 5 Corynebacterium spp | NA | Clinical cure: 72.2% (endocarditis), Relapse: 4% (overall) | 6.7% (not serious) |
| Bryson-Cahn et al., 2019 | Retrospective cohort study | 9 | OPAT 100.0% All drug injection users | 100.0% (range 4–32 days) | Dalbavancin 1000 mg single dose or 1000 mg + 500 mg | 7 MRSA, 2 MSSA | 30 days | Clinical cure: 55.6% (44.4% lost to follow-up) | NA | None |
| Vazquez Deida et al., 2020 | Retrospective observational case series | 8 | 7 Right-sided IE, 1 Left-sided IE | 100.0% (range 8–35 days) | 1500 mg single dose | 7 MRSA, 1 MSSA | 90 days | Clinical success: 75.0% (25% lost to follow-up), Relapse: 0.0% | 7.0% (overall) |

*https://doi.org/10.2147/DDDT.S313756*
| Study (Year)      | Study Type            | OPAT (%) | Clinical Success (%) | Relapse (%) | Mortality (%) |
|------------------|-----------------------|----------|----------------------|-------------|---------------|
| Bouza et al., 2018<sup>17</sup> | Retrospective cohort study, multicentric | 7        | OPAT 73.9% (median 18 days) | 97.1%        | NA            |
|                  |                       |          | Dalbavancin 1500 mg single dose or 1000 mg (LD) + 500 mg | 2 CoNS 2 Enterococcus spp 1 MRSA 1 Streptococcus spp 1 NA | NA            |
| Bai et al., 2020<sup>18</sup> | Retrospective cohort study, multicentric | 6 (82 overall patients included in the study) | OPAT 57.8% | Dalbavancin 1000 mg (LD) + 500 mg or 1500 mg single dose | 28 CoNS 24 MRSA 14 MSSA 6 E. faecalis 5 E. faecium 5 Others | 30–180 days | Clinical success at end of study: 83.3% | Relapse: 17.8% (overall in the study) | 7.0% |
| Ajaka et al., 2020<sup>19</sup> | Retrospective cohort study | 4        | 2 definite – 2 possible Active injection drug user: 100% | 100.0% (range 11–27 days) | Dalbavancin 1500 mg single-dose | 2 MRSA 1 MSSA 1 S. mitis | 90 days | Clinical success: 25.0% Microbiological eradication: 25.0% | Relapse 0.0% | NA |
| Nunez-Nunez et al., 2018<sup>20</sup> | Prospective observational | 3 (19 overall patients included in the study) | OPAT 65% | Dalbavancin 1500 mg single dose or 1500 mg + 1500 mg or 1000 mg + 500 mg | 7 MRSA 6 CoNS 5 MSSA 1 E. faecalis 1 E. faecium | 90 days | Clinical success: 100.0% | Relapse: 0.0% | 4.5% (not serious; overall) |
| Bork et al., 2019<sup>21</sup> | Retrospective cohort study, multicentric | 1 (28 overall patients included in the study) | 1 CDE OPAT 100% | 100.0% (median 13.5 days) | NA | 30–90 days | Overall clinical success: 71% (CDE 100% at 30-day; 0% at 90-day) | Relapse prior 90-day (CoNS + Corynebacterium spp.) | 10.7% (overall) |

(Continued)
| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Dalbavancin Regimen | Isolates | Duration of Follow-Up | Outcome | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) |
|-----------------------------|-------------|----------------|------------------|-------------------------------|---------------------|----------|-----------------------|---------|----------------------------------------|-----------------------------|
| Spaziante et al., 2019<sup>42</sup> | Case report | 1 | Prosthetic valve IE No eligible for surgical treatment | Daptomycin + ceftriaxone + rifampicin (7 weeks) | Dalbavancin 1500 mg for five doses (Long-term chronic suppressive therapy) | MRSE + S. mitis | 140 days | Clinical success: 100.0% Microbiological eradication: 100.0% Mortality rate: 0.0% | None | None |
| Hakim et al., 2020<sup>43</sup> | Case report | 1 | Native tricuspid-valve IE in injection drug-user | Vancomycin + cefepime Cefadroxil + TMP/SMX (3 days) | Dalbavancin 1500 mg (LD) + 500 mg once-weekly for 5 weeks | MSSA | 6 weeks | Clinical success: 100.0% Microbiological eradication: 100.0% Mortality rate: 0.0% | None | None |
| Steele et al., 2017<sup>44</sup> | Case report | 1 | Native tricuspid-valve IE in injection drug-user | Vancomycin (Day 1–4) Daptomycin (Day 5–27) | Dalbavancin 1000 mg (LD) + 500 mg once-weekly for 4 weeks | MRSA | 64 days | Clinical success: 0.0% Microbiological eradication: 0.0% Mortality rate: 0.0% | Resistance development (VISA – Dalbavancin MIC 0.5 mg/L) | None |
| Kussmann et al., 2018<sup>45</sup> | Case report | 1 | CDE | Piperacillin-Tazobactam + Cefalexin (4 months) | Dalbavancin (6 months – dose not available) | S. aureus (MSSA/MRSA) Dalbavancin MIC: 0.5 mg/L (first strain) 1 mg/L (second strain) | 6 months | Clinical success: 0.0% Microbiological eradication: 0.0% Mortality rate: 0.0% | Resistance development | None |
retrospectively assessed 27 patients affected by IE (16 native valve IE, 6 prosthetic valve IE, and 5 cardiac device-related endocarditis) treated with dalbavancin. Prior antibiotic therapy use was reported in 88.9% of cases. Dalbavancin was administered as a LD of 1000 mg followed by 500 mg once-weekly, or 1000 mg biweekly after 1500 mg LD. Median duration was 6 weeks. *Staphylococcus aureus* (33.3%) was the most frequently isolated pathogen. At 6 months, clinical success and microbiological eradication was respectively found in 92.6% and 92.6% of patients. A case of resistance development occurred in a patient MSSA cardiac device-related endocarditis who was treated with dalbavancin on a once-weekly basis for 30 weeks. AEs occurred in 7.4% of patients. The other two cases reported the emergence of dalbavancin resistance in an IE setting. Steele et al. described a case of a 27-year pregnant woman affected by a native tricuspid-valve IE caused by MRSA receiving dalbavancin for 4 weeks after clinical failure with the use of vancomycin and daptomycin. Eleven days after the last dose of dalbavancin, a vancomycin-resistant *Staphylococcus aureus* showing a dalbavancin MIC of 0.5 mg/L grew from blood cultures, and antibiotic therapy was switched to daptomycin in association with ceftaroline. Kussmann et al. described a case of a 36-year-old man affected by cardiac device-related endocarditis caused by MSSA/MRSA receiving long-term suppressive therapy for 6 months with dalbavancin. Two different MRSA strains exhibiting dalbavancin MIC of 0.5 mg/L and 1 mg/L were isolated from blood cultures. Antibiotic treatment was switched to fusidic acid in association with rifampicin, resulting in negative blood cultures and improved clinical conditions.

**Bloodstream and Vascular Infections**

Ten observational studies, one case series, and six case reports assessed the efficacy and safety of dalbavancin for the treatment of bloodstream infections (BSIs) and vascular infections (Table 3). Overall, 144 patients affected by BSIs or vascular infections were treated with dalbavancin, resulting in a clinical success of 81.3%. Different dalbavancin regimens in terms of dose and duration were administered. In a case of prosthetic graft infection due to *Enterococcus faecium*, dalbavancin was successfully administered as long-term suppressive therapy for a total of 62 weeks. Overall, relapse was reported in 3.5% of cases. The development of resistance to dalbavancin has emerged in only one case. In the DALBACEN cohort study, 49 patients affected by
| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Antibiotic and Dosing | Isolates | Duration of Follow-Up | Outcome | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) |
|----------------------------|--------------|----------------|------------------|-------------------------------|-----------------------|----------|----------------------|---------|-------------------------------|-------------------------------|
| Hidalgo-Tenorio et al., 2019<sup>31</sup> | Retrospective cohort study | 49 | 69.4% complicated BSI OPAT 93.8% | 93.9% (median 8 days) 44.9% daptomycin 22.4% vancomycin 20.4% ceftriaxone 18.4% linezolid | Dalbavancin 1000–1500 mg single-dose or 1000 mg (LD) + 500 mg | 17 CoNS 15 MSSA 9 MRSA 2 Streptococcus spp. 2 E. faecium 1 E. faecalis 1 Other | 90 days | Clinical success: 100.0% Microbiological eradication: 97.2% Mortality rate: 0.0% | Relapse: 0.0% (not serious) |
| Ajaka et al., 2020<sup>79</sup> | Retrospective cohort study | 14 | Active injection drug user: 57.1% | 100% (range 2–30 days) | Dalbavancin 1500 mg single dose or 1000 mg (LD) + 500 mg or 1500 mg + 1000/1500 mg | 8 MRSA 3 MSSA 2 GAS 2 CoNS 1 S. lugdunensis 1 E. faecalis | 90 days | Clinical success: 50.0% Microbiological eradication: 50.0% Mortality rate: 21.4% | Relapse: 14.3% NA |
| Vazquez Deida et al., 2020<sup>16</sup> | Retrospective observational case series | 13 | 9 complicated (2 with pneumonia) 4 uncomplicated | 100.0% (range 6–27 days) | 1500 mg single dose | 10 MSSA 3 MRSA 1 GAS 1 S. anginosus | 90 days | Clinical success: 84.6% (15.4% lost to follow-up) | Relapse: 0.0% 7.0% (overall) |
| Bryson-Cahn et al., 2019<sup>15</sup> | Retrospective cohort study | 13 | OPAT 100.0% All drug injection users | 100.0% (range 3–16 days) | Dalbavancin 1000 mg single dose or 1000 mg + 500 mg | 13 S. aureus | 30 days | Clinical cure: 53.8% (7.7% clinical failure; 38.5% lost to follow-up) | NA None |
| Study                      | Design               | N                  | Types of Infections                                 | Dalbavancin Dose and Administration | Sensitivity to Dalbavancin | Clinical Cure (%) | Relapse (%) | Relapse (Serious) (%) |
|----------------------------|----------------------|--------------------|-----------------------------------------------------|------------------------------------|--------------------------|-------------------|--------------|---------------------|
| Dinh et al., 2019          | Retrospective        | 12 (75 overall     | 5 vascular infections                               | 98.7% Dalbavancin 1000–1500 mg    | 32 CoNS                 | NA                | 4% (overall) | 6.7% (not serious) |
|                            | cohort study,        | patients included  | [4 CR-BSI, 3 BSI]                                   | single-dose or 1000 mg + 500 mg    |                         |                   |              |                     |
|                            | multicentric         | in the study       |                                                     | or 1000 mg + 1000 mg + 1500 mg     |                         |                   |              |                     |
|                            |                      |                    |                                                     | weekly up to > 4 doses             |                         |                   |              |                     |
| Bouza et al., 2018         | Retrospective        | 10                 | 8 CR-BSI, 2 other endovascular infections            | 97.1% Dalbavancin 1500 mg          | 4 MRSA                  | NA                | 0.0%         | 13.0% (2.9% serious) |
|                            | cohort study,        |                    | OPAT 73.9%                                          | single-dose or 1000 mg (LD) + 500 mg |                         |                   |              |                     |
|                            | multicentric         |                    |                                                     |                                    |                         |                   |              |                     |
|                            |                      |                    |                                                     |                                    |                         |                   |              |                     |
| Bork et al., 2019          | Retrospective        | 10 (28 overall     | 6 Endovascular                                     | 100.0% (median 13.5 days)         | 8 MRSA                  | NA                | 0.0%         | 4.5% (not serious) |
|                            | cohort study,        | patients included  | [4 BSI, OPAT 100%]                                  |                                     |                         |                   |              |                     |
|                            | multicentric         | in the study       |                                                     |                                     |                         |                   |              |                     |
|                            |                      |                    |                                                     |                                     |                         |                   |              |                     |
| Nunez-Nunez et al., 2018   | Prospective          | 5 (19 overall      | OPAT 65%                                            | 100%                               | 7 MRSA                  | NA                | 0.0%         | 4.5% (not serious; overall) |
|                            | observational        | patients included  |                                                     | Dalbavancin 1500 mg single-dose    |                         |                   |              |                     |
|                            |                      | in the study       |                                                     | or 1500 mg + 1500 mg or 1000 mg + 500 mg |                         |                   |              |                     |

(Continued)
### Table 3 (Continued).

| Author, Year and Reference     | Study Design                                      | No. of Patients | Clinical Features                                                                 | Prior Antibiotic and Duration | Antibiotic and Dosing                                                                 | Isolates                                      | Duration of Follow-Up | Outcome                                                                 | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) |
|--------------------------------|--------------------------------------------------|----------------|------------------------------------------------------------------------------------|------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------|----------------------|----------------------------------------------------------------------|-------------------------------------|-----------------------------------|
| Bai et al., 2020               | Retrospective cohort study, multicentric          | 4 (82 overall patients included in the study) | 4 CR-BSI OPAT 57.8%                                                              | 82.5%                        | Dalbavancin 1000 mg (LD) + 500 mg or 1500 mg single dose                              | 28 CoNS, 24 MRSA, 14 MSSA, 6 E. faecalis, 5 E. faecium, 5 Others | 30–180 days          | Clinical success at end of study: 50.0%                              | Relapse: 17.8% (overall in the study) | 7.0%                              |
| Wunsch et al., 2019            | Retrospective cohort study, multicentric          | 3 (101 overall patients included in the study) | 3 CR-BSI 49% OPAT                                                                 | 100.0%                       | Dalbavancin 1500 mg single dose or 1500 mg + 1500 mg or 1500 mg + 500 mg            | 28 CoNS, 14 MRSA, 8 MSSA, 7 Enterococcus spp., 5 Streptococcus spp., 4 P. aerogenes, 21 Others | 90 days after the last dose of dalbavancin | Overall clinical success: 89% (66.7% CR-BSI) 90-day mortality rate: 5% (33.3% CR-BSI) Overall clinical failure: 5% | NA                                  | 3% (overall)                      |
| Nunez-Nunez et al., 2018       | Prospective observational                        | 1 (19 overall patients included in the study) | 1 Long-term suppressive therapy in prosthetic graft infection                     | 100%                        | Dalbavancin 750 mg (LD) + 375 mg weekly for a total of 62 doses (IHD)                  | 1 E. faecium                                                                                 | 90 days              | Clinical success: 100.0%                                             | Relapse: 0.0%                                         | None                              |
| Hitzenbichler et al., 2020     | Case series                                      | 4              | 4 Long-term suppressive therapy for BSI due to intravascular source                | 100%                        | Dalbavancin 1000 mg (LD) + 375/500 mg/weekly or 1500 mg (LD) + 1000 mg biweekly       | 2 E. faecalis, 1 E. faecium + CoNS, 1 MSRA                                              | NA                                  | Overall clinical success: 50% Overall mortality rate: 75%             | Relapse: 25% (C. difficile infection – Rash) | 50%                              |
| Study                                    | Case report | Type          | Antimicrobial regimen                                                                 | Pathogen       | Clinical success | Relapse | Adverse events |
|-----------------------------------------|-------------|---------------|----------------------------------------------------------------------------------------|----------------|------------------|---------|----------------|
| Jones et al., 2018<sup>1</sup>          | I           | CR-BSI with associated empyema OPAT | Vancomycin + Piperacillin-Tazobactam + Levofloxacin Dalbavancin 1500 mg single dose | E. faecalis    | NA               | 100.0%  | None           |
| Cho et al., 2015<sup>2</sup>            | I           | BSI           | Cefazolin (6 days) Dalbavancin 1000 mg + 500 mg | MSSA           | 14 days          | 100.0%  | None           |
| Ciccullo et al., 2019<sup>3</sup>       | I           | Bacteremic prosthetic vascular graft infection | Vancomycin + Rifampicin Dalbavancin 1000 mg + 500 mg (overall six weeks) | MRSA           | 4 months         | 100.0%  | None           |
| Martinez-Sanz et al., 2017<sup>4</sup>  | I           | Septic thrombophlebitis | Daptomycin + Cloxacillin Daptomycin + Cefazolin Dalbavancin 1500 mg/2 weeks for 6 weeks (overall 3 doses) | MSSA           | 12 weeks         | 100.0%  | None           |
| Howard-Anderson et al., 2019<sup>5</sup> | I           | BSI to LVAD infection | Cephalexin Doxycycline TMP/SMX Dalbavancin 1500 mg weekly for 10 weeks then 1500 mg biweekly (Overall 235 days) | MSSA           | 235 days         | 100.0%  | None           |
| Werth et al., 2018<sup>6</sup>          | I           | CR-BSI        | Vancomycin 8 days Dalbavancin 1000 mg single dose | MRSA           | 12 days          | 0.0%   | 100.0% Emergence of VISA |

**Abbreviations:** AEs, adverse events; BSI, bloodstream infection; CoNS, coagulase-negative Staphylococcus; CR-BSI, catheter-related bloodstream infection; GAS, group A Streptococcus; LD, loading dose; LVAD, left ventricular assistance device; MRSE, methicillin-resistant Staphylococcus epidermidis; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; NA, not available; OPAT, outpatient parenteral antimicrobial therapy; TMP/SMX, cotrimoxazole; VISA, vancomycin-intermediate Staphylococcus aureus.
BSIs (of which 69.4% were complicated) receiving at least one dose of dalbavancin were assessed. 93.9% of patients received dalbavancin for a median duration of 8 days, daptomycin and vancomycin being the most frequent agents used. Dalbavancin was administered as a single-dose of 1000–1500 mg, or 1000 mg LD followed by 500 mg at day 8. *Staphylococcus aureus* was the most frequent pathogen isolated (49.0%). Clinical success was documented in 100.0% of patients at 90 days (including two cases of BSI caused by *Enterococcus faecium*), with no case of relapse or resistance development. AEs occurred in 4.8% of patients, although none of these was serious. Different retrospective cohort studies and case series reported the efficacy of dalbavancin for the treatment of endovascular infections, with a clinical success ranging from 50–80% of cases. Notably, Werth et al. reported a case of occurrence of dalbavancin resistance in a 34-year man affected by a CR-BSI due to MRSA. The patient received a single dalbavancin dose of 1000 mg after eight days of ineffective therapy with vancomycin because of inability to achieve optimal serum concentrations. After 12 days, a VISA was isolated from urine culture exhibiting a 4-fold increase in MIC for dalbavancin and vancomycin compared with previous isolate retrieved in blood cultures.

**Bone and Joint Infections**

Bone and joint infections represent the most frequent dalbavancin off-label indication. Specifically, one RCT, 12 observational studies, one case series, and 11 case reports assessed the efficacy and safety of dalbavancin for the treatment of bone and joint infections (Table 4). Overall, 483 patients affected by bone and joint infections were treated with dalbavancin, resulting in a clinical success rate of 84.5%. Different dalbavancin regimens in terms of dose and duration were administered. Relapse occurred in up to 12.5% of cases. Notably, no case of resistance development to dalbavancin was reported. As previously mentioned, Rappo et al. found no difference in clinical cure rate at the end of treatment in 70 patients affected by osteomyelitis randomized to dalbavancin compared with 10 subjects receiving SOC (97% vs 88%; p = NS). Morata et al. retrospectively collected 64 patients with bone and joint infections (namely 45 and 19 respectively affected by implant-associated infections and osteomyelitis). *Staphylococcus epidermidis* was isolated in almost half of cases. A clinical success or improvement was respectively reported in 97.7% and 89.5% of subjects with implant-associated infections and osteomyelitis. Relapse was described in only two patients. Wunsch et al. retrospectively assessed 62 patients (32 affected by prosthetic joint infections and 30 with osteomyelitis) receiving dalbavancin as second-line therapy for bone and joint infections. Dalbavancin was administered as a 1500 mg single dose, 1000 mg LD followed by 500 mg at day 8, or two 1500 mg doses one week apart. Clinical success was reported in 93.6% of patients, and no case of relapse was documented. Overall, AEs were reported in only 3% of cases. Interestingly, Bai et al. stratified clinical outcome according to different type of bone and joint infection in 50 patients receiving dalbavancin (1500 mg single dose or 1000 mg LD followed by 500 mg at day 8). At 6 months, clinical success was respectively reported in 89.7% of osteomyelitis/spondylodiscitis, 76.5% of prosthetic joint infections, and 75% of septic arthritis. Similarly, 6-month clinical cure was respectively found in 100% of acute septic arthritis, 60% of osteomyelitis, 50% of spondylodiscitis, and 38% of prosthetic joint infections in 50 patients affected by bone and joint infections retrospectively collected. Notably, Almangour et al. found a trend for higher 90-day clinical cure in 11 patients receiving dalbavancin for the treatment of *Staphylococcus aureus* osteomyelitis compared with 11 subjects treated with SOC, including vancomycin, daptomycin, or ceftazolin according to *Staphylococcus aureus* susceptibility (100.0% vs 72.7%; p = 0.06). Different retrospective studies and case reports documented the efficacy of dalbavancin for the treatment of bone and joint infections caused by *Enterococcus faecium* or *Corynebacterium striatum*.

**Other off-Label Indications**

Four retrospective cohort studies and two case reports assessed the efficacy and safety of dalbavancin for other off-label indications (Table 5). Overall, 16 cases of deep sternal wound infection associated with mediastinitis, three cases of intra-abdominal infection, two cases of mediastinitis, two cases of pneumonia, and one case each of sinusitis and pyelonephritis were reported. Clinical cure was documented in 92.0% of cases. Relapse was reported in a patient affected by deep sternal wound infection, and in a case of mediastinitis. No occurrence of resistance development to dalbavancin was found, and no safety issues emerged.
Table 4 Summary of the Evidence Investigating the off-Label Use of Dalbavancin for the Treatment of Bone and Joint Infections

| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Antibiotic and Dosing | Isolates | Duration of Follow-Up | Outcome | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) |
|---------------------------|--------------|----------------|------------------|------------------------------|-----------------------|----------|----------------------|---------|--------------------------------------|----------------------------------|
| Morata et al., 2019<sup>14</sup> | Retrospective cohort study, multicentric | 64 | 45 Implant-associated infection 19 Bone or joint infection | 100.0% | Dalbavancin LD 1000 mg (N= 50) – 1500 mg (N= 12) – 500 mg (N= 1) – 750 mg (N= 1) Single dose (N= 9) Followed by 500 mg/week (N= 54; median duration 5 weeks) Followed by 1500 mg biweekly (N= 1; four total doses) | 30 S. epidermidis 14 S. aureus 5 E. faecalis 4 E. faecium 3 C. striatum 3 Streptococcus spp. 2 S. lugdunensis 1 S. capitis 1 S. pneumoniae | Latest medical visit | Clinical success or improvement: 97.7% (implant-associated infections) Clinical success or improvement: 89.5% (bone or joint infections) Mortality rate: 6.3% | Relapse: 3.1% | NA |
| Wunsch et al., 2019<sup>13</sup> | Retrospective cohort study, multicentric | 62 (101 overall patients included in the study) | 32 prosthetic joint infection 30 osteomyelitis OPAT 49% | 100.0% | Dalbavancin 1500 mg single dose or 1500 mg or 1000 mg + 500 mg | 28 CoNS 14 MSSA 8 MRSA 7 Enterococcus spp. 5 Streptococcus spp. 4 P. acnes 21 Others | 90 days after the last dose of dalbavancin | Overall clinical success: 89% (93.6% bone and joint infections) 90-day mortality rate: 5% (3.2% bone and joint infections) Overall clinical failure: 5% (3.2% bone and joint infections) | NA | 3% (overall) |

(Continued)
Table 4 (Continued).

| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Antibiotic and Dosing | Isolates | Duration of Follow-Up | Outcome | Relapse Rate | Resistance Development | Safety (Overall Proportion of AEs) |
|----------------------------|--------------|-----------------|-------------------|------------------------------|------------------------|----------|----------------------|---------|--------------|------------------------|----------------------------------|
| Bai et al., 2020<sup>14</sup> | Retrospective cohort study, multicentric | 50 (82 overall patients included in the study) | 25 Osteomyelitis 17 Prosthetic joint infections 4 Spondylodiscitis 4 Septic arthritis | OPAT 57.8% | 82.5% | Dalbavancin 1000 mg (LD) + 500 mg or 1500 mg single dose | 28 CoNS 24 MRSA 14 MSSA 6 E. faecalis 5 E. faecium 5 Others | 30–180 days | Clinical success at end of study: 89.7% (osteomyelitis – spondylodiscitis) 76.5% (prosthetic joint infections) 75.0% (septic arthritis) | Relapse: 17.8% (overall in the study) | 7.0% |
| Dinh et al., 2019<sup>14</sup> | Retrospective cohort study, multicentric | 48 (75 overall patients included in the study) | OPAT 49.3% | 98.7% | Dalbavancin 1000–1500 mg single-dose or 1000 mg + 500 mg or 1000 mg + 1000 mg or 1500 mg/weekly up to > 4 doses | 32 CoNS 23 MSSA 14 MRSA 5 E. faecalis 5 Corynebacterium spp. Range median MIC 0.032–0.064 mg/L | NA | Clinical cure: 76.1% (bone and joint infections) | Relapse: 4% (overall) | 6.7% (not serious) |
| Study                        | Type of Study                                      | Study Duration | Number of Patients | Diagnosis                          | Treatment                                  | Clinical Cure | Clinical Failure | Adverse Events |
|------------------------------|---------------------------------------------------|----------------|--------------------|------------------------------------|--------------------------------------------|---------------|------------------|----------------|
| Tobudic et al., 2019<sup>23</sup> | Retrospective cohort study                        | 6 months       | 46 (72 overall patients included in the study) | 20 Osteomyelitis, 14 Spondylodiscitis, 8 Prosthetic joint infections, 4 Acute septic arthritis | Dalbavancin 1000 mg LD + 500 mg weekly, 1500 mg LD + 1000 mg biweekly, 1500 mg day 1 + 1500 mg day 8 | 81%           | 23.9%            | NA             |
| Bouza et al., 2018<sup>27</sup> | Retrospective cohort study, multicentric          | 6 months       | 33                 | 20 Prosthetic joint infection, 12 Osteomyelitis, 1 Septic arthritis | OPAT 73.9% Dalbavancin 1500 mg single dose or 1000 mg (LD) + 500 mg | 97.1% (median 18 days) | NA              | 8.7% (rash N = 2; nausea N = 1; hyperglycaemia N = 1) |

(Continued)
| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Antibiotic and Dosing | Isolates | Duration of Follow-Up | Outcome | Relapse Rate | Safety (Overall Proportion of AEs) |
|---------------------------|--------------|----------------|-------------------|-------------------------------|------------------------|----------|----------------------|---------|--------------|----------------------------------|
| Almangour et al., 2019    | Retrospective cohort study, multicentric | 31             | 31 Osteomyelitis Bacteraemic 32.3% | 84% (median 20 days) | Dalbavancin 1500 mg + 1500 mg or 1000 mg LD + 500 mg weekly for up to 13 weeks or 1500 mg LD + 500 mg weekly for up to 3 weeks or 1000 mg x 2 followed by 500 mg weekly or 1500 mg single dose | 15 MRSA 12 MSSA 2 mixed gram-positive 1 CoNS 1 NA | 3 months after the completion of the antibiotic course | Clinical success: 90.3% | Relapse: 3.2% | None |
| Buzon et al., 2019        | Retrospective cohort study | 16             | All prosthetic joint infections (8 total hip and 8 total knee arthroplasty infections) | NA | Dalbavancin LD 1500 mg + 500 mg day 8 and then 500 mg biweekly or LD 1000 mg + 500–1 000 mg/ week | 7 CoNS 4 MRSA 4 E. faecium 4 E. faecalis | 503 days (median) | Clinical success: 75% Clinical failure: 12.5% Mortality rate: 6.3% | Relapse: 12.5% | 12.5% (not-serious; leukopenia N= 1; rash N= 1) |
| Study Authors | Study Design | Study Population | Site of Infection | OPAT | Therapeutic Regimen | Duration | Clinical Success/Yield | Infectious Pathogen | Complications |
|---------------|--------------|------------------|-------------------|------|---------------------|----------|------------------------|-------------------|--------------|
| Bork et al., 2019 [1] | Retrospective cohort study, multicentric | 15 (28 overall patients included in the study) | 13 Osteomyelitis 1 Prosthetic joint infection 1 Septic arthritis | OPAT 100% (median 13.5 days) | 8 MRSA 6 MSSA 4 CoNS 8 Other 5 NA | 30–90 days | Overall clinical success: 71% (Bone and joint infection 50% at 30-day) | NA | 10.7% (overall) |
| Almangour et al., 2020 [6] | Retrospective matched-cohort study | 11 | 11 Osteomyelitis | No prior antibiotic treatment for >7 days | Dalbavancin 1500 mg day 1 + 1500 mg day 8 or 1000 mg LD + 500 mg weekly for 4–13 weeks vs Daptomycin or Vancomycin or Ceftazolin | 90 days | 90-day clinical cure: 100% (dalbavancin) vs 72.7% (SOC) [p = 0.062] | 6 MRSA 5 MSSA | None |
| Bryson-Cahn et al., 2019 [5] | Retrospective cohort study | 10 | 7 Osteomyelitis 3 Septic arthritis OPAT 100.0% All drug injection users | 100.0% (range 1–29 days) | Dalbavancin 1000 mg single dose or 1000 mg + 500 mg | 30 days | Clinical cure: 60.0% (30.0% clinical failure; 10.0% lost to follow-up) | 13 S. aureus | NA |
| Nunez-Nunez et al., 2018 [10] | Prospective observational | 10 (19 overall patients included in the study) | 6 Osteomyelitis 4 Implanted prosthetic device infection | 100% | Dalbavancin 1500 mg single dose or 1500 mg + 1500 mg or 1000 mg + 500 mg | 90 days | Clinical success: 100.0% | 7 MRSA 6 CoNS 5 MSSA 1 E. faecalis 1 E. faecium | Relapse: 4.5% (not serious; overall) |
| Vazquez Deida et al., 2020 [16] | Retrospective observational case series | 6 | 5 Osteomyelitis 1 Joint infection | 100.0% (range 28–35 days) | 1500 mg single dose | 90 days | Clinical success: 83.3% (16.7% clinical failure) | 3 MRSA 2 MSSA 1 GAS 1 MRSE | Relapse: 7.0% (overall) |

(Continued)
| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Antibiotic and Dosing | Isolates | Duration of Follow-Up | Outcome | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) |
|-----------------------------|-------------|----------------|-------------------|------------------------------|------------------------|---------|----------------------|---------|------------------------------|---------------------------------|
| Durante-Mangoni et al., 2020 | Case report | 1 | Osteomyelitis with psoas abscess | Daptomycin + Rifampicin for 21 days and then Teicoplanin + Rifampicin for 7 days | Dalbavancin 1000 mg (day 1/8) + 500 mg/weekly for 6 weeks | Methicillin-resistant *Staphylococcus haemolyticus* | 9 months | Clinical success: 100.0% | Relapse: 0.0% | None |
| Molina Collada et al., 2017 | Case report | 1 | Septic arthritis in a native knee | Linezolid for 7 days and then Teicoplanin (duration not reported) | Dalbavancin 1500 mg single dose | *Corynebacterium striatum* Dalbavancin MIC <0.125 mg/L | 6 months | Clinical success: 100.0% | Relapse: 0.0% | None |
| Azamgarhi et al., 2019 | Case report | 1 | Infected massive endoprosthetic replacement of the hip | Vancomycin + Ceftriaxone + Amikacin for 5 days | Dalbavancin 1500 mg for two doses | MRSE Dalbavancin MIC <0.047 mg/L | 16 months | Clinical success: 100.0% | Relapse: 0.0% | None |
| Trujillano Ruiz et al., 2019 | Case report | 1 | Prosthetic infection of the hip | Vancomycin and then ciprofloxacin + rifampicin for 4 months, and then + Linezolid for 4 weeks | Dalbavancin 1000 mg LD + 500 mg/week for 3 weeks | MRSE | 1 month | Clinical success: 100.0% | Relapse: 0.0% | None |
| Barbero Allende et al., 2021 | Case report | 1 | Femoral osteomyelitis after surgical intervention for osteosarcoma | Minocycline for 2 years | Dalbavancin 1500 mg every 4 weeks as long-term suppressive therapy | MRSE | 2 years | Clinical success: 100.0% | Relapse: 0.0% | None |
| Reference          | Type         | Case ID | Diagnosis                                           | Treatment                                                                 | Pathogen | Duration | Clinical Success | Relapse | Other Notes     |
|--------------------|--------------|---------|-----------------------------------------------------|---------------------------------------------------------------------------|-----------|----------|------------------|---------|-----------------|
| Loupa et al., 2020 | Case report  | 1       | Diabetic foot osteomyelitis                         | Daptomycin + Tigecycline + Dalbavancin 1500 mg single dose at discharge and then linezolid for two weeks and tedizolid for one week 1500 mg second dose one month after the first | *E. faecium* | 18 months | 100.0%           | 0.0%    | None            |
| Carrion Madronal et al., 2020 | Case report | 1       | Prosthetic infection of the hip                     | Vancomycin for two weeks, then linezolid for two weeks + Dalbavancin LD 1000 mg + 500 mg weekly for 7 weeks in combination with linezolid | MRSE      | 16 weeks | 100.0%           | 0.0%    | None            |
| Vates et al., 2018 | Case report  | 1       | Spondylodiscitis D1-L1 + paravertebral abscess + ileo-femoral bypass vascular infection | Daptomycin + rifampicin for one month, then vancomycin + Dalbavancin LD 750 mg + 375 mg weekly for 7 weeks | MRSA      | NA       | 100.0%           | 0.0%    | None            |
| Almangour et al., 2017 | Case report | 1       | Native vertebral osteomyelitis with bacteraemia     | Vancomycin and then daptomycin for a total of 12 weeks + Dalbavancin 1000 mg/week for 2 weeks + 500 mg/week for additional 6 weeks | MRSA      | 3 months | 100.0%           | 0.0%    | (MRSA bacteraemia) |
| Ramirez-Hidalgo et al., 2018 | Case report | 1       | Prosthetic knee infection                           | Daptomycin for 10 days + Dalbavancin LD 1000 mg weeks + 500 mg/week for 3 weeks | MRSE      | 9 months | 100.0%           | 0.0%    | None            |

(Continued)
Quality of Life

The favourable PK/PD properties of dalbavancin resulting in a single weekly administration and abbreviated dosing schedule may allow for the treatment of endocarditis, osteomyelitis, and vascular infections in an outpatient setting, thus leading to shorter length of hospital stay, reduction in cost and healthcare resource use, and improvement in patient satisfaction. Although different studies\(^{37,71–76}\) assessed the advantages of dalbavancin from a pharmacoeconomic point of view, the consequent impact on quality of life has been less investigated. Early discharge and shorter hospital stays are associated with improved patient quality of life, mobility, and the prevention of non-infectious and infectious catheter-related complications.\(^8\) In the ENHANCE pre-post trial,\(^{77}\) McCarthy et al. found a significant improvement in work productivity and activity impairment (impairment while working [47.9% vs 8.9%; \(p = 0.01\)], overall work impairment [59.3% vs 18.0%; \(p = 0.01\)], and non-work related impairment of activity [60.2% vs 18.5%; \(p<0.001\)]) in 43 patients treated with dalbavancin for acute bacterial skin and skin structure infections (ABSSSIs) in the post-period compared with 48 subjects receiving usual care in the pre-period. Furthermore, a trend to significant improvement in quality-of-life outcomes was reported with dalbavancin (\(p = 0.07\)). However, no difference in absenteeism between pre- and post-period was found. In a post-hoc analysis\(^{78}\) of a phase 3 RCT involving 698 adult patients with ABSSSIs and treated with dalbavancin (386 and 312 respectively managed in outpatient and inpatient settings), outpatients reported significantly greater convenience and satisfaction with antibiotic treatment and care setting than inpatients. Specifically, a greater number of outpatients versus inpatients reported that antibiotic treatment did not interfere at all with daily activities (74% vs 42%; \(p<0.001\)) and that they were easily able to modify their schedule to receive antibiotic therapy (97% vs 76%; \(p<0.001\)).

Safety

Dalbavancin exhibited an excellent safety profile both in RCTs and observational studies investigating in- and off-label indications.\(^{79}\) Dunne et al.\(^{80}\) performed a pooled analysis of 3002 patients enrolled in seven phase II/III RCTs receiving dalbavancin (\(N = 1778\)) or comparators (\(N = 1224\)), including vancomycin, linezolid, nafcillin, oxacillin, and cephalosporins. Patients treated with dalbavancin experienced a significantly lower number of overall

---

Table 4 (Continued)

| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Antibiotic and Dosing | Outcome | Relapse – Resistance Development | Safety (Overall Proportion of AEs) |
|---------------------------|--------------|----------------|------------------|-----------------------------|-----------------------|---------|---------------------------------|----------------------------------|
| Alvarez-Otero et al., 2019 | Case report  | 1               | Acromioclavicular arthritis associated with bacteremic multiple pyomyositis and subcutaneous abscesses | Clindamycin for 5 weeks | Dalbavancin 1500 mg + 1500 mg one month later | Clinical success: 100.0% | Relapse: 0.0% | None | |
| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Antibiotic and Dosing | Isolates | Duration of Follow-Up | Outcome | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) |
|----------------------------|--------------|----------------|------------------|-----------------------------|-----------------------|---------|----------------------|---------|-------------------------------------|----------------------------------|
| Bartoletti et al., 2019⁹¹⁸ | Retrospective cohort study, multicentric | 15             | 15 Deep sternal wound infections with mediastinitis | 100.0% Teicoplanin Daptomycin Vancomycin | Dalbavancin 1500 mg + 1500 mg or 1000 mg (LD) + 500 mg | 7 MRSA 6 MRSE 2 CoNS | 6 months | Clinical success: 93.0% | Relapse: 7.0% | NA |
| Bouza et al., 2018¹⁷³⁷ | Retrospective cohort study, multicentric | 4              | 3 IAI 1 Sinusitis OPAT 73.9% | 97.1% (median 18 days) | Dalbavancin 1500 mg single dose or 1000 mg (LD) + 500 mg | 3 Enterococcus spp. 1 Streptococcus spp. | NA | Clinical success: 100.0% | Relapse: 0.0% | 13.0% (2.9% serious) |
| Dinh et al., 2019¹⁴³⁴ | Retrospective cohort study, multicentric | 2 (75 overall patients included in the study) | 2 Mediastinitis OPAT 49.3% | 98.7% | Dalbavancin 1000–1500 mg single-dose or 1000 mg + 500 mg or 1000 mg + 1000 mg or 1500 mg/weekly up to > 4 doses | 32 CoNS 23 MSSA 14 MRSA 5 E. faecalis 5 Corynebacterium spp. Range median MIC 0.032–0.064 mg/L | NA | Clinical cure: 50.0% (mediastinitis) | Relapse: 4% (overall) | 6.7% (not serious) |

(Continued)
| Author, Year and Reference | Study Design | No. of Patients | Clinical Features | Prior Antibiotic and Duration | Antibiotic and Dosing | Isolates | Duration of Follow-Up | Outcome | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) | Antibiotic and Dosing | Isolates | Duration of Follow-Up | Outcome | Relapse Rate – Resistance Development | Safety (Overall Proportion of AEs) |
|---------------------------|--------------|----------------|------------------|-------------------------------|------------------------|----------|----------------------|---------|------------------------|--------------------------------|-----------------------|----------|----------------------|---------|------------------------|--------------------------------|
treatment-emergent AEs compared with those receiving other antibiotics (44.9% vs 46.8%; p = 0.012). AEs reported in at least 2% of subjects receiving dalbavancin in RCTs were: nausea, headache, diarrhoea, vomiting, and rash.80 Furthermore, no late-onset AEs were reported.80 A recent meta-analysis including seven RCTs investigating dalbavancin in different settings (ABSSSIs, CR-BSIs, and osteomyelitis) found no significant difference in terms of any AEs (OR 1.58; 95% CI 0.82–3.02), adverse drug reactions (OR 0.85; 95% CI 0.61–1.19), and specific AEs (including nausea, headache, constipation, hypertension, vomiting, rash, pyrexia, anaemia, fungal infection, alanine aminotransferase elevation and gamma-glutamyl transferase elevation) between dalbavancin and comparators.81 When compared with vancomycin or linezolid, the incidence of diarrhoea was significantly lower in patients receiving dalbavancin (OR 0.38; 95% CI 0.21–0.68).81 Notably, there was no significant difference in serious AEs (OR 0.80; 95% CI 0.55–1.17).81

The excellent safety profile was also confirmed in real-life studies evaluating dalbavancin use in off-label settings (e.g., endocarditis, BSIs, osteomyelitis, joint infections), in which the overall proportion of AEs ranged from 0% to 13%.28–34,36–38,40,41,54 Furthermore, most AEs were not serious, with serious AEs ranging between 0.0% and 2.9%.28–38,40,41,54 Notably, Veve et al.30 found a significantly lower proportion of AEs in patients treated with dalbavancin for off-label indications (namely osteoarticular infections, IE, and BSIs) compared with vancomycin or daptomycin (3% vs 14%; p = 0.013). Dalbavancin was well-tolerated by children ranging in age from 3 months to 17 years.82,83 Additionally, Dunne et al. found no QTc interval prolongation with dalbavancin administration at a dosage up to 1500 mg in healthy volunteers.84 Finally, Mahoney et al. reported no short-term or long-term AEs in a case of unintentional receipt of 3000 mg of dalbavancin within 20 hours, with the possible exception of mild diarrhoea.

**Expert Opinion**

In the last five years, several reports assessing the use of dalbavancin in challenging off-label clinical scenarios have emerged, highlighting the innovative role of this agent for the management of Gram-positive infections usually requiring long-term therapy. Overall, in the 800 identified patients receiving dalbavancin for off-label indications, a positive clinical outcome was reported in a remarkable proportion of subjects, namely in 84.3% of bone and joint infections, 81.3% of BSIs (mainly CR-BSIs or endovascular infections), 81.1% of IE, and 92.0% of other indications (including deep sternal wound infections associated with mediastinitis, intra-abdominal infections, pneumonia, pyelonephritis, and sinusitis; Table 6). Notably, in these settings dalbavancin showed a significantly higher clinical cure rate and lower infection-related readmission with respect to comparators (namely vancomycin and daptomycin). Furthermore, the occurrence of relapse was limited (below 10%), while resistance development to dalbavancin was reported in only four patients (three cases of infection caused by MRSA and one due to MSSA). Similarly, the emergence of serious safety issues with dalbavancin was negligible.

Notably, the use of dalbavancin in these challenging scenarios exhibits some relevant advantages, specifically allowing for avoiding daily in-hospital intravenous antibiotic treatment or complications associated with outpatient antimicrobial therapy. Indeed, the unique PK/PD properties of dalbavancin resulting in a single weekly administration and abbreviated dosing schedule may allow for the treatment of Gram-positive infections in an

---

**Table 6 Cumulative Efficacy Reported with the Use of Dalbavancin for off-Label Therapeutic Indications**

| Off-Label Therapeutic Indications             | Clinical Success | Relapse | Resistance Development |
|-----------------------------------------------|------------------|---------|------------------------|
| Endocarditis                                  | 120/148 (81.1%)  | 7/114 (6.1%) | 3/114 (2.6%)          |
| Bloodstream infections                        | 117/144 (81.3%)  | 7/140 (5.0%) | 1/140 (0.7%)         |
| Bone and joint infections                     | 408/483 (84.5%)  | 31/387 (8.0%) | 0/387 (0.0%)     |
| Others                                        | 23/25 (92.0%)    | 2/25 (8.0%)   | 0/25 (0.0%)         |
| Deep sternal wound infections                 | 15/16 (93.8%)    | 1/16 (6.2%)   | 0/16 (0.0%)         |
| Intrabdominal infection                       | 3/3 (100.0%)     | 0/3 (0.0%)    | 0/3 (0.0%)          |
| Mediastinitis                                 | 1/2 (50.0%)      | 1/2 (50.0%)   | 0/2 (0.0%)          |
| Pneumonia                                     | 2/2 (100.0%)     | 0/2 (0.0%)    | 0/2 (0.0%)          |
| Sinusitis                                     | 1/1 (100.0%)     | 0/1 (0.0%)    | 0/1 (0.0%)          |
| Pyelonephritis                                | 1/1 (100.0%)     | 0/1 (0.0%)    | 0/1 (0.0%)          |
outpatient setting. This represents a crucial aspect in view of the current COVID-19 era, in which patients requiring prolonged (e.g., IE or bone and joint infections) or long-term suppressive (endovascular infections) antibiotic therapy after hospital discharge due to severe Gram-positive infections are at increased risk for contracting and/or transmitting COVID-19 due to extensive contact with the healthcare system. Furthermore, dalbavancin allows a limited healthcare resource use coupled with a lower length of hospital stay, resulting in non-negligible cost savings. In this scenario, dalbavancin could play a key role in enhancing outpatient treatment of several infections requiring long-term antibiotic therapy.

Real-world evidence showed a wide heterogeneity in dalbavancin dosing schedule and treatment duration in the different clinical scenarios. Consequently, an attempt to standardize the therapeutic approach in patients requiring dalbavancin for the management of IE, BSI, or bone and joint infections could be made (Figure 1). A single infusion of 1500 mg, or 1500 mg followed by a second dose of 1000–1500 mg one-week apart could be proposed as the dalbavancin dosing schedule in patients affected by IE. In subjects with prosthetic IE not eligible for surgical treatment or affected by cardiac device-related endocarditis requiring long-term chronic suppression therapy, once-weekly or twice-weekly infusion of dalbavancin 500–1500 mg could be suggested. A single infusion of dalbavancin 1500 mg could be adequate for the treatment of complicated BSI, as well as in the case of CR-BSI. In patients affected by BSI due to prosthetic graft infection or other intravascular source (e.g., left ventricular assistance device infection), a long-term suppression therapy consisting in once-weekly or twice-weekly infusion of dalbavancin 500–1500 mg could be suggested. Dalbavancin dosing schedule proposed by Dunne et al.2 (1500 mg followed by a second infusion of 1500 mg one-week apart) could be proposed in patients affected by bone and joint infections, considering that this regimen ensures great efficacy against *Staphylococcus aureus* for up to 5 weeks. In the fifth week, a clinical assessment may allow for considering the administration of an additional dose for prolonging effective treatment.27 In this case, a therapeutic drug monitoring-guided approach could also be implemented to assess the achievement of optimal dalbavancin PK/PD target.

Figure 1 A proposal of algorithm for dalbavancin dosing schedule in off-label therapeutic indications.

Abbreviations: BSI, bloodstream infection; CDE, cardiac device-associated endocarditis; IE, infective endocarditis; OA, osteoarticular infection.
The role of dalbavancin combination therapy in off-label indications remains an unmet clinical need. Several in vitro studies showed the synergistic effect of dalbavancin in combination with ceftaroline, cefazolin, daptomycin, rifampicin, and linezolid in reducing the MIC for MRSA, daptomycin non-susceptible, and heterogeneous VISA strains. However, real-world experiences are limited to a single case report of dalbavancin and linezolid combination therapy for the management of a prosthetic joint infection.

Conclusion
Dalbavancin shows remarkable efficacy and good tolerability in different challenging scenarios, emerging as a promising alternative in the management of IE, complicated BSI, and osteoarticular infections. The role of dalbavancin is further enhanced in the current COVID-19 era, in which ineluctable hospitalization and empowerment of territorial medicine are strongly required. Further studies assessing the best dosing schedule and the role of combination therapy in each specific scenario are warranted.

Acknowledgment
This work was supported by an unrestricted grant from Angelini S.P.A.

Disclosure
Dr M Gatti reports grants from Angelini S.p.A., during the conduct of the study. Prof. M Andreoni has participated in advisory boards and/or received speaker honoraria from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, ViV Healthcare and has received study grants from Merck Sharp & Dohme, outside the submitted work. Prof. F Pea reports personal fees from Angelini, during the conduct of the study; personal fees from Angelini, Basilea Pharmaceutica, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, Thermo Fisher, and Accelerate Diagnostics, outside the submitted work; has participated in speaker’s bureau for Accelerate Diagnostics, Angelini, Basilea Pharmaceutica, Gilead, Hikma, MSD, Pfizer, Sanofi-Aventis, Shionogi, Thermo Fisher, and as consultant for Angelini, Basilea Pharmaceutica, Gilead, MSD, Pfizer, Shionogi, outside the submitted work; Prof P Viale has served as a consultant for bioMérieux, Gilead, Merck Sharp & Dohme, Navirha, Nordic Pharma, Pfizer, Thermo-Fisher, and Venatorx, and received payment for serving on the speaker’s bureaus for Correvo, Gilead, Merck Sharp & Dohme, Nordic Pharma, and Pfizer, outside the submitted work. The authors report no other potential conflicts of interest for this work.

References
1. Andreoni M, Bassetti M, Corrao S, De Rosa FG, Esposito V, Falcone M, Girosi P, Pea F, Poggioli S, Tascini C, Venditti M, Viale P. The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. Expert Rev Anti Infect Ther. 2021 Mar 16:1–10. doi:10.1080/14787210.2021.1894130. Epub ahead of print.
2. Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-dose and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849–1855. doi:10.1128/AAC.04550-14
3. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–2179. doi:10.1056/NEJMoa1310480
4. Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–551. doi:10.1093/cid/civ982
5. Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–S575. doi:10.1093/cid/ciz830
6. Thomas G, Henao-Martinez AF, Franco-Paredes C, Chastain DB. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: a systematic review. Int J Antimicrob Agents. 2020;56(3):106069. doi:10.1016/j.ijantimicag.2020.106069
7. Herrera-Hidalgo L, de Alarcón A, López-Cortes LE, et al. Enterococcus faecalis endocarditis and outpatient treatment: a systematic review of current alternatives. Antibiotics (Basel). 2020;9(10). doi:10.3390/antibiotics9100657
8. Durante-Mangoni E, Gambardella M, Iula VD, et al. Current trends in the real-life use of dalbavancin: report of a study panel. Int J Antimicrob Agents. 2020;56(4):106107. doi:10.1016/j.ijantimicag.2020.106107
9. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012;54(3):393–407. doi:10.1093/cid/cir482
10. Luque Paz D, Lakhar I, Tattevin P. A review of current treatment strategies for infective endocarditis. Expert Rev Anti Infect Ther. 2021;19(3):297–307. doi:10.1080/14787210.2020.1822165
11. Mansour O, Keller S, Katz M, Townsend JL. Outpatient parenteral antimicrobial therapy in the time of COVID-19: the urgent need for better insurance coverage. Open Forum Infect Dis. 2020;7(8):ofaa287. doi:10.1093/ofid/ofaa287
12. Dash RP, Babu RJ, Srinivas NR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis (Lond). 2017;49(7):483–492. doi:10.1080/23744235.2017.1296968
13. Carruthers TJ, Chittenden JT, Critchley I. Dalbavancin population pharmacokinetic modeling and target attainment analysis. Clin Pharmacol Drug Dev. 2020;9(1):21–31. doi:10.1002/cpdd.695
14. Jones RN, Stillwell MG, Sader HS, Fritsche TR, Goldstein BP. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States surveillance program (2004). Diagn Microbiol Infect Dis. 2006;54(2):149–153. doi:10.1016/j.diagmicrobio.2005.08.015
15. Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016). Int J Antimicrob Agents. 2018;51(4):608–611. doi:10.1016/j.ijantimicag.2017.12.011
16. Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005;45(11):1279–1287. doi:10.1177/0091270005280378
17. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. *Antimicrob Agents Chemother.* 2007;51(5):1633–1642. doi:10.1128/AAC.01264-06

18. Lepak A, Marchillo K, VanHecker J, Andes D. Impact of glycopeptide resistance in staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target. *Antimicrob Agents Chemother.* 2015;59(12):7833–7836. doi:10.1128/AAC.01717-15

19. Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. *J Clin Pharmacol.* 2009;49(4):465–476. doi:10.1177/0002248708310362

20. Van Mattle ET, Teitelbaum I, Kiser TH. Intravenous and intraperitoneal pharmacokinetics of dalbavancin in perioperative dialysis patients. *Antimicrob Agents Chemother.* 2020;64(5). doi:10.1128/AAC.02089-19

21. Corona A, Agarossi A, Veronese A, Cattaneo D, D’Avolio A. Therapeutic drug monitoring of dalbavancin treatment in severe necrotizing fasciitis in 3 critically ill patients: a grand round. *Ther Drug Monit.* 2020;42(2):165–168. doi:10.1097/FTD.0000000000000729

22. Di Pilato V, Ceccherini F, Sennati S, et al. In vitro time-kill kinetics of dalbavancin against Staphylococcus spp. biofilms over prolonged exposure times. *Diagn Microbiol Infect Dis.* 2020;96(2):114901. doi:10.1016/j.diagmicrobio.2019.114901

23. Fernández J, Greenwood-Quaintance KE, Patel R. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. *Diagn Microbiol Infect Dis.* 2016;85(4):449–451. doi:10.1016/j.diagmicrobio.2016.05.009

24. Neudorfer K, Schmidt-Malan SM, Patel R. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci. *Diagn Microbiol Infect Dis.* 2018;90(1):58–63. doi:10.1016/j.diagmicrobio.2017.09.015

25. Nicolau DP, Sun HK, Seltzer E, Dowell JA. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. *J Antimicrob Chemother.* 2007;60(3):681–684. doi:10.1093/jac/dkm263

26. Rapp O, Dunne MW, Puttagunta S, et al. Epithelial lining fluid and plasma concentrations of dalbavancin in healthy adults after a single 1500-milligram infusion. *Antimicrob Agents Chemother.* 2019;63(11). doi:10.1128/AAC.01024-19

27. Cojotti PG, Rinaldi M, Zamparini E, et al. Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections. *Antimicrob Agents Chemother.* 2021. doi:10.1128/AAC.02260-20

28. Rapp O, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. *Open Forum Infect Dis.* 2019;6(1):ofy331. doi:10.1093/ofid/ofy331

29. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive bacteria in an intravenous drug user. *Clin Infect Dis.* 2005;40(3):374–380. doi:10.1086/427283

30. Veve MP, Patel N, Smith ZA, Yeager SD, Wright LR, Shorman MA. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections. *Int J Antimicrob Agents.* 2020;56(6):106210. doi:10.1016/j.ijantimicag.2020.106210

31. Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. *Ann Clin Microbiol Antimicrob.* 2019;18(1):30. doi:10.1186/s12941-019-0329-6

32. Tobucic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of vienna. *Clin Infect Dis.* 2018;67(5):795–798. doi:10.1093/cidi/ciy279

33. Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. *Int J Infect Dis.* 2019;81:210–214. doi:10.1016/j.ijid.2019.02.013
50. Ciccolino A, Giuliano G, Segala VF, Taddei E, Farinacci D, Pallavicini F. Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection. *Infection, 2020*;48(2):309–310. doi:10.1007/s10150-019-01379-2

51. Howard-Anderson J, Pouch SM, Sexton ME, et al. Left ventricular assist device infections and the potential role for dalbavancin: a case report. *Open Forum Infect Dis*. 2019;6(9):ofz235. doi:10.1093/ofid/ofz235

52. Martínez-Sanz J, Gijón de la Santa L, Torralba M. Treatment with dalbavancin in a patient with septic thrombophlebitis of the internal jugular vein due to *Staphylococcus aureus* after insertion of an implantable cardioverter defibrillator. *Enferm Infect Microbiol Clin*. 2018;36(6):389–390. doi:10.1016/j.eimc.2017.10.002

53. Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. *Infection*. 2019;47(6):1013–1020. doi:10.1007/s10150-019-01354-x

54. Morata L, Cobo J, Fernández-Sampedro M, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. *Antimicrob Agents Chemother*. 2019;63(5). doi:10.1128/AAC.02280-18

55. Almangour TA, Perry GK, Teriff CM, Alhifani AA, Kaye KS. Dalbavancin for the treatment of gram-positive osteomyelitis: effectiveness and potential utility. *Diag Microbiol Infect Dis*. 2019;93(3):213–218. doi:10.1016/j.diagmicrobio.2018.10.007

56. Almangour TA, Perry GK, Alhifani AA. Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: a retrospective matched cohort study. *Saudi Pharm J*. 2020;28(4):460–464. doi:10.1016/j.jspjs.2020.02.007

57. Buzón Martín L, Mora Fernández M, Perales Ruiz JM, et al. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: a proposal for a low dose strategy. A retrospective cohort study. *Rev Esp Quimioter*. 2019;32(6):532–538.

58. Azamgarhi T, Donaldson J, Shah A, Warren S. Dalbavancin to treat methicillin-resistant *Staphylococcus epidermidis*. *J Glob Antimicrob Resist*. 2019;7:36–39. doi:10.1016/j.jgar.2019.06.007

59. Loupa CV, Lykoudi E, Meimeti E, et al. Successful treatment of diabetic foot osteomyelitis with dalbavancin. *Med Arch*. 2020;74(3):243–245. doi:10.5455/medarch.2020.74.243-245

60. Carrión Madroñal IM, Sánchez Del Moral R, Abad Zamora JM, Martínez Marcos FJ. Dalbavancin combined with linezolid in prostatic infection. *Rev Esp Quimioter*. 2020;33(2):147–148. doi:10.37201/rq/1807

61. Yates R, Rodríguez SJ, Martínez ME, Martínez JA. Experiencia clínica sobre un caso de osteomielitis tratado con dalbavancina [Clinical experience on a case of osteomyelitis treated with dalbavancin]. *Rev Esp Quimioter*. 2018. Spanish. Epub ahead of print.

62. Almangour TA, Fletcher V, Alessa M, Alhifani AA, Tabb D. Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant *Staphylococcus aureus*: a case report. *Am J Case Rep*. 2017;18:1315–1319. doi:10.26295/ajcr.905930

63. Molina Collada J, Rico Nieto A, Díaz de Bustamante Ussia M, Balsa Criado A. Septic arthritis in a native knee due to *Corynebacterium diphtheriae*. *Reumatol Clin*. 2018;14(5):301–302. doi:10.1016/j.reuma.2017.01.013

64. Trujillano Ruiz A, Mesquida Riera J, Serrano Fabiá MA, Riera Pérez E, Mejía Benard A, Taberner Ferrer MD. Tratamiento prolongado con dalbavancina en infección protésica de cadera por *Staphylococcus epidermidis* resistente a meticina [Prolonged treatment with dalbavancin in prosthetic hip infection by methicillin-resistant *Staphylococcus epidermidis*]. *Rev Esp Quimioter*. 2019;52(2):203–204. Spanish. Epub 2019 Mar 13.

65. Barbero Allende JM, García Sánchez M, Culebras López AM, Agudo Alonso R. Suppressive antibiotic treatment with dalbavancin. A case report. *Rev Esp Quimioter*. 2021;34(2):151–153. doi:10.37201/req/1052020
83. Gonzalez D, Bradley JS, Blumer J, et al. Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age. *Pediatr Infect Dis J*. 2017;36(7):645–653. doi:10.1097/INF.0000000000001538

84. Dunne MW, Zhou M, Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. *Int J Antimicrob Agents*. 2015;45(4):393–398. doi:10.1016/j.ijantimicag.2014.12.021

85. Mahoney MV, Padival S. Receipt of supratherapeutic dalbavancin. *Am J Health Syst Pharm*. 2020;77(5):326–328. doi:10.1093/ajhp/zxaa337

86. Abdul-Mutakabbir JC, Kebriaei R, Stamper KC, et al. Dalbavancin, vancomycin and daptomycin alone and in combination with cefazolin against resistant phenotypes of Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. *Antibiotics (Basel)*. 2020;9(10). doi:10.3390/antibiotics9100696

87. Kebriaei R, Rice SA, Stamper KC, Rybak MJ. Dalbavancin alone and in combination with ceftaroline against four different phenotypes of Staphylococcus aureus in a simulated pharmacodynamic/pharmacokinetic model. *Antimicrob Agents Chemother*. 2019;63(4). doi:10.1128/AAC.01743-18

88. Aktas G, Derbentli S. In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains. *J Antimicrob Chemother*. 2017;72(2):441–443. doi:10.1093/jac/dkw416

89. Baldoni D, Furustrand Tafin U, Aeppli S, et al. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model. *Int J Antimicrob Agents*. 2013;42(3):220–225. doi:10.1016/j.ijantimicag.2013.05.019